Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22596144 | 0.92 | EPHX1 (0.42) | EPHX1EPHX2KDM1ARIPK1TRPV1 | |
| SCHEMBL4999465 | 0.87 | EPHX1 (0.41) | EPHX1EPHX2KDM1ARIPK1 | |
| SCHEMBL12452605 | 0.83 | HSP90AA1 (0.40) | EPHX1HSP90AA1HSP90AB1LIPE | |
| SCHEMBL470951 | 0.80 | ALDH1A1 (0.48) | EPHX1EPHX2KDM1ANPC1 | |
| SCHEMBL4131266 | 0.80 | EPHX1 (0.45) | EPHX1EPHX2KDM1ARIPK1 | |
| SCHEMBL8486161 | 0.80 | EPHX1 (0.45) | EPHX1EPHX2KDM1ARIPK1ESR1 | |
| SCHEMBL1470211 | 0.80 | EPHX1 (0.42) | EPHX1EPHX2KDM1AESR1ESR2 | |
| SCHEMBL8164423 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL2798175 | 0.78 | EPHX1 (0.44) | EPHX1EPHX2KDM1ARIPK1 | |
| Hydrochloric Acid SCHEMBL2794765 | 0.78 | EPHX1 (0.44) | EPHX1EPHX2KDM1ARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166103-A | EGFR inhibitor and application thereof | 江苏先声药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-9809541-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170183308-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. (US) | 2017-06-29 | — | — | US | disclosed |
| EP-1954287-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2011-11-16 | — | — | EP | disclosed |
| WO-2007068552-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | HIMMELSBACH FRANK | 2007-06-14 | — | — | US | disclosed |
| EP-1428534-B1 | BENZOFURAZAN DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | UNIV CALIFORNIA (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1428534-A1 | BENZOFURAZAN DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | The Regents of the University of California (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-0960105-B1 | BENZOFURAZAN COMPOUNDS THAT ENHANCE AMPA RECEPTOR ACTIVITY | UNIV CALIFORNIA (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6730677-B2 | TREATING MEMORY IMPAIRMENT; ENHANCE EXCITATORY SYNAPTIC ACTIVITY IN ORDER TO RESTORE AN IMBALANCE BETWEEN BRAIN SUBREGIONS, AS IN TREATMENT OF SCHIZOPHRENIA OR SCHIZOPHRENIFORM BEHAVIOR. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-05-04 | — | — | US | disclosed |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | CORTEX PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | disclosed |
| US-20020055498-A1 | Benzofurazan compounds for enhancing glutamatergic synaptic responses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-05-09 | — | — | US | disclosed |
| US-6313115-B1 | ALLEVIATE IMPAIRMENT OF MEMORY, OR OTHER COGNITIVE FUNCTIONS CAUSED BY HYPOGLUTAMATERGIC CONDITION OR BY DEFICIENCY IN NUMBER OR STRENGTH OF EXCITATORY SYNAPSES OR IN NUMBER OF AMPA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-11-06 | — | — | US | disclosed |
| US-6110935-A | A PROMOTER FOR N-METHYL-D-ASPARTIC ACID (NMDA) RECEPTORS, USEFUL FOR SUCH THERAPEUTIC PURPOSES AS FACILITATING THE LEARNING OF BEHAVIORS, TREATING SCHIZOPHRENIA, MEMORY IMPAIRMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0960105-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | The Regents of the University of California (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998035950-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183308-A1 | LSD1 Inhibitors | KDM1B, KDM1A, KDM3A | EPHX1 1289/4885EPHX2 1894/4885KDM1A 2/4885 |
| US-20020055498-A1 | Benzofurazan compounds for enhancing glutamatergic synaptic responses | GRIN1, GABRE, GABRG1 | EPHX1 770/4885EPHX2 2534/4885KDM1A 2069/4885 |
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | BPHL, CYP11B2, CYP11B1 | EPHX1 2805/4885EPHX2 1639/4885KDM1A 4284/4885 |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | GRIN1, GABRE, GRM1 | EPHX1 566/4885EPHX2 1549/4885KDM1A 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.